Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic competition and safety warnings cast mist over Horizant's horizons

This article was originally published in Scrip

Executive Summary

FDA approval of Horizant (gabapentin enacarbil) offers patients with postherpetic neuralgia an improved dosing regimen over available treatment options. However, the Xenoport drug faces fierce competition in the US, where it will be marketed by GlaxoSmithKline, from generic gabapentin and the once daily gabapentin formulation Gralise from Depomed. Moreover, safety warnings surrounding driving impairments are likely to serve as a deterrent to prescribing.

You may also be interested in...



Respiratory Effectiveness Group Summit: real-life use of COPD, asthma treatments

The recent Respiratory Effectiveness Group (REG) Summit provided clinicians, general practitioners, pulmonologists, and representatives from the industry with the opportunity to discuss real-life effectiveness research in respiratory disease. Dr Natasha Spiller was there to look at a new battle ground for top-selling mainstay respiratory therapies, Spiriva, Symbicort and Advair.

BI, GSK, Novartis hale and hearty at COPD party

It has been an eventful week in chronic obstructive pulmonary disease (COPD). New safety data emerged for Spiriva Respimat (tiotropium; Boehringer Ingelheim) and encouraging analyses from Novartis’ LABA/LAMA Ultibro Breezhaler from the European Respiratory Society (ERS) Annual Congress: while Anoro (umeclidinium/vilanterol), GlaxoSmithKline’s fixed-dose long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) inhaler, has been recommended for approval by the US FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC).

European Ultibro nod gives Novartis boost in COPD race

The expected entry of Ultibro Breezhaler into the COPD market following the positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use on 25 July will considerably advance Novartis's position within the market.

Topics

Related Companies

UsernamePublicRestriction

Register

SC017702

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel